Whitehawk Therapeutics, Inc.(WHWK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

WHWK Whitehawk Therapeutics, Inc.

Market Closed 12-12 16:00:00 EST

2.32

-0.18

-7.20%

盘后2.32

+0.000.00%

16:52 EST

High2.54	Low2.24	Vol136.50K
Open2.47	D1 Closing2.50	Amplitude12.00%
Mkt Cap109.34M	Tradable Cap50.51M	Total Shares47.13M
T/O324.36K	T/O Rate0.63%	Tradable Shares21.77M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"WHWK","market":"US","secType":"STK","nameCN":"Whitehawk Therapeutics, Inc.","latestPrice":2.32,"timestamp":1765573200000,"preClose":2.5,"halted":0,"volume":136495,"hourTrading":{"tag":"盘后","latestPrice":2.32,"preClose":2.32,"latestTime":"16:52 EST","volume":389,"amount":905.161,"timestamp":1765576379566},"delay":0,"floatShares":21770230,"shares":47128362,"eps":-0.309934,"marketStatus":"Market Closed","change":-0.18,"latestTime":"12-12 16:00:00 EST","open":2.47,"high":2.54,"low":2.24,"amount":324359.5520125,"amplitude":0.12,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-0.309934,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765789200000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":2.5,"preHourTrading":{"tag":"盘前","latestPrice":2.44,"preClose":2.5,"latestTime":"09:18 EST","volume":613,"amount":1488.3895621000001,"timestamp":1765549109460},"postHourTrading":{"tag":"盘后","latestPrice":2.32,"preClose":2.32,"latestTime":"16:52 EST","volume":389,"amount":905.161,"timestamp":1765576379566},"volumeRatio":0.9893301220688607,"impliedVol":0.288,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/WHWK/wiki","defaultTab":"wiki","newsList":[{"id":"2588069405","title":"Whitehawk Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Chief Medical Officer Margaret Dugan","url":"https://stock-news.laohu8.com/highlight/detail?id=2588069405","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588069405?lang=en_us&edition=fundamental","pubTime":"2025-12-03 05:46","pubTimestamp":1764712019,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc. has filed an initial statement of beneficial ownership  identifying Margaret Dugan, who serves as the company's Chief Medical Officer, as the beneficial owner. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on December 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDL5nQT0v:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK","BK4139"],"gpt_icon":0},{"id":"2588778476","title":"BRIEF-Whitehawk Therapeutics Appoints Margaret Dugan, As Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588778476","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588778476?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:42","pubTimestamp":1764596564,"startTime":"0","endTime":"0","summary":"BRIEF-Whitehawk Therapeutics Appoints Margaret Dugan, As Chief Medical OfficerDec 1 (Reuters) - Whitehawk Therapeutics Inc WHWK.O:WHITEHAWK THERAPEUTICS APPOINTS MARGARET DUGAN, MD, AS CHIEF MEDICAL O","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUAC1DBBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","WHWK"],"gpt_icon":0},{"id":"2588270727","title":"WhiteHawk Therapeutics Appoints Margaret Dugan, Md, as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588270727","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588270727?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594001,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251201:nTUAC1DBBQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","WHWK"],"gpt_icon":0},{"id":"2588313720","title":"Press Release: Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2588313720","media":"Dow Jones","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588313720?lang=en_us&edition=fundamental","pubTime":"2025-12-01 21:00","pubTimestamp":1764594000,"startTime":"0","endTime":"0","summary":"Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic. MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. , an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate  cancer treatments, today announced the appointment of Margaret Dugan, MD, as Chief Medical Officer . Dr. Dugan brings more than 30 years of global oncology drug development experience, with extensive expertise in early-stage clinical development and regulatory strategy.\"I'm delighted to welcome Margaret to Whitehawk. Her strategic insight and deep early-development expertise strengthen our ability to design efficient, signal-rich clinical studies and rapidly translate our ADC portfolio into potentially impactful therapies for patients,\" said Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics.Whitehawk Therapeutics is an oncology therapeutics compan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","WHWK","BK4539","BK4196","MD","BK4080","BK4231","ADC","BK4007","BK4139"],"gpt_icon":0},{"id":"2586325225","title":"Whitehawk Therapeutics CEO to Join Piper Sandler Healthcare Conference Fireside Chat","url":"https://stock-news.laohu8.com/highlight/detail?id=2586325225","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586325225?lang=en_us&edition=fundamental","pubTime":"2025-11-26 21:00","pubTimestamp":1764162042,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc. will participate in a fireside discussion at the Piper Sandler 37th Annual Healthcare Conference in New York City on December 3, 2025, at 12:30 PM ET. The event will feature Dave Lennon, PhD, President and CEO of Whitehawk Therapeutics, and will be available via live webcast on the company's investor relations website, with a replay available for approximately 30 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on November 26, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251126:nNDLbRqzy9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4127","WHWK","BK4139","PIPR"],"gpt_icon":0},{"id":"2584931441","title":"Whitehawk Therapeutics unveils ADC pipeline and preclinical data in new corporate presentation","url":"https://stock-news.laohu8.com/highlight/detail?id=2584931441","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584931441?lang=en_us&edition=fundamental","pubTime":"2025-11-18 19:41","pubTimestamp":1763466078,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc. has released a corporate presentation detailing its advancements in antibody-drug conjugate  technology. The company's pipeline features three ADC assets, including HWK-007 targeting PTK7 and HWK-016 targeting MUC16, both expected to enter Phase 1 clinical trials with indications across several cancer types such as non-small cell lung, ovarian, endometrial, and mesothelioma. The presentation highlights the novel linker-payload technology utilized in Whitehawk's ADC platform, which is designed for enhanced potency, stability, and safety compared to average topoisomerase I inhibitor ADCs. Preclinical data show greater tumor potency, improved stability in circulation, and a higher safety margin in animal models. As of September 30, 2025, Whitehawk reported $162.6 million in cash, with an anticipated runway into 2028. Key investors include Kalehua and Ally Bridge Group. You can access the full presentation through the link below.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251118:nNDL84wPLZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK","BK4139"],"gpt_icon":0},{"id":"2581481093","title":"Whitehawk Therapeutics reports Q3 net loss of $17.7 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2581481093","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581481093?lang=en_us&edition=fundamental","pubTime":"2025-11-06 21:03","pubTimestamp":1762434232,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc. reported a net loss of $17.7 million for the third quarter ended September 30, 2025, compared to a net loss of $12.5 million for the same period in 2024. Cash, cash equivalents, and short-term investments totaled $162.6 million as of September 30, 2025, up from $47.2 million at the end of 2024. The company stated that its current cash position is expected to fund operations into 2028. During the quarter, Whitehawk continued preparations for IND filings of HWK-007 and HWK-016 by the end of 2025, and plans an IND filing for HWK-206 by mid-2026. The company also presented data at the AACR-NCI-EORTC conference confirming PTK7 as a highly expressed tumor marker, supporting its ADC development strategy.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as fin","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nNDL8npPtg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","WHWK"],"gpt_icon":0},{"id":"2579498148","title":"Whitehawk Therapeutics Inc  expected to post earnings of 7 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2579498148","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579498148?lang=en_us&edition=fundamental","pubTime":"2025-10-31 22:16","pubTimestamp":1761920179,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc  expected to post earnings of7cents a share - Earnings Preview Whitehawk Therapeutics Inc WHWK.OQ WHWK.O is expected to  show a rise in quarterly revenue when it reports  re","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251031:nL8N3WC1LE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK","BK4139"],"gpt_icon":0},{"id":"2578465265","title":"Whitehawk Therapeutics Advances HWK-007 ADC Targeting PTK7 in Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2578465265","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578465265?lang=en_us&edition=fundamental","pubTime":"2025-10-25 00:30","pubTimestamp":1761323429,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc. announced new data from a real-world analysis evaluating Protein Tyrosine Kinase 7  as a broadly expressed and clinically relevant target across solid tumors. The findings, presented at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, indicate that PTK7 is the third most highly expressed tumor marker among clinically validated and emerging antibody drug conjugate  targets, present in approximately 70% of tumors. PTK7 expression was found to be stable across different histologic subtypes, disease stages, and metastatic statuses in cancers such as lung, ovarian, and endometrial. Whitehawk Therapeutics is developing HWK-007, a PTK7-targeting ADC utilizing a cleavable linker for delivery of a Topoisomerase I inhibitor payload, with plans to submit an Investigational New Drug application to the U.S. Food and Drug Administration by year-end and initiate clinical evaluation in non-small cell lung cancer, ovarian, and en","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251024:nNDL2dcXFY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK","BK4139"],"gpt_icon":0},{"id":"2575744129","title":"Whitehawk Shares Rise After Forming Collaboration With Tempus AI to Advance Oncology Research","url":"https://stock-news.laohu8.com/highlight/detail?id=2575744129","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575744129?lang=en_us&edition=fundamental","pubTime":"2025-10-16 21:32","pubTimestamp":1760621574,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics  shares were sharply higher Thursday after the company formed a multi-year collaboration with Tempus AI  to leverage Tempus' real-world dataset to advance biomarker-driven research and further Whitehawk Therapeutics' oncology pipeline, Tempus said.The collaboration will focus on Whitehawk Therapeutics' antibody drug conjugates portfolio, which includes three assets designed to target proteins that are broadly expressed in high-potential cancer indications, such as lung and gynecological cancers, the company said.Shares of Tempus AI and Whitehawk were up 5.3% and 54.7%, respectively, in early trading.Price: 3.28, Change: +1.17, Percent Change: +55.45","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["WHWK","TEM","LU1861559042.SGD","LU1861558580.USD","BK4139","BK4613","BK4121","BK4611","TEM.AU","BK7095"],"gpt_icon":1},{"id":"2567166651","title":"BUZZ-Australia's WhiteHawk jumps on AI deal with private co","url":"https://stock-news.laohu8.com/highlight/detail?id=2567166651","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567166651?lang=en_us&edition=fundamental","pubTime":"2025-09-15 08:48","pubTimestamp":1757897292,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's WhiteHawk jumps on AI deal with private co** WhiteHawk WHK.AX jumps 9.1% to A$0.012; set for strongest session since September 5** Cybersecurity firm enters three-year partnership with private entity DoxAI Australia** Partnership to help co introduce automation technologies to enterprise and government clients to optimise compliance processes, strengthen data security, among others** Agreement includes distribution of co's cyber compliance, supply chain analytics platform** YTD, WHK gains 9.1%  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250915:nL3N3V200V:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7049","BK4139","WHK.AU","BK7024","WHWK"],"gpt_icon":0},{"id":"2564804288","title":"Whitehawk Therapeutics Inc. CEO to Participate in Morgan Stanley Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2564804288","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564804288?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:02","pubTimestamp":1756814561,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc. will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8, 2025, in New York City. The company's president and CEO, Dave Lennon, PhD, will present in a fireside chat at 4:50 PM ET.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on September 02, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250902:nNDL2Fv77L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1162221912.USD","LU0795875169.SGD","LU0106831901.USD","LU1668664300.SGD","LU1989772840.SGD","LU2133065610.SGD","LU2271345857.HKD","BK4534","LU1244550577.SGD","LU2089283258.USD","LU2089284900.SGD","LU1363072403.SGD","LU0158827948.USD","WHWK","LU1074936037.SGD","LU1989772923.USD","LU0158827781.USD","LU2023251221.USD","LU0098860793.USD","BK4588","LU1732799900.SGD","BK4516","LU2347655156.SGD","LU0971096721.USD","BK4127","BK4581","LU0225283273.USD","LU0106261372.USD","LU1244550221.USD","IE00BZ1G4Q59.USD","LU2111349929.HKD","LU2357305700.SGD","BK4504","LU0320765646.SGD","LU0006306889.USD","IE00BKVL7J92.USD","LU0882574139.USD","LU1244550494.USD","LU1548497426.USD","LU1732800096.USD","LU1720051017.SGD","BK4139","LU0267386448.USD","LU0912757837.SGD","LU2028103732.USD","LU0314104364.USD","BK4585","LU1720051108.HKD","LU0795875086.SGD","LU0234570918.USD"],"gpt_icon":0},{"id":"2557856684","title":"Whitehawk Therapeutics Reports Second Quarter 2025 Financial Results And Recent Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2557856684","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557856684?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:46","pubTimestamp":1754570765,"startTime":"0","endTime":"0","summary":"Aug 7 (Reuters) - Whitehawk Therapeutics Inc ::*WHITEHAWK THERAPEUTICS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND RECENT HIGHLIGHTS*WHITEHAWK THERAPEUTICS INC - ANTICIPATES CASH RUNWAY INTO 202","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nRSD5s7RCY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK","BK4139"],"gpt_icon":0},{"id":"2557639175","title":"Whitehawk Therapeutics Inc. Unveils Presentation Highlighting Transition to ADC-Focused Company and Advancements in Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2557639175","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557639175?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:26","pubTimestamp":1754569616,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc. Unveils Presentation Highlighting Transition to ADC-Focused Company and Advancements in Cancer Therapy. Whitehawk Therapeutics Inc. recently held a corporate presentation outlining its transition into an Antibody-Drug Conjugate -focused company. The presentation highlighted Whitehawk's focus on advanced ADC platform technology designed to minimize off-target toxicity and enhance therapeutic stability. The company is working on three key assets, HWK-007, HWK-016, and HWK-206, each targeting overexpressed proteins in various cancer types, including lung, ovarian, and neuroendocrine tumors. These assets are anticipated to progress to clinic by mid-2026. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be inter","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nNDL4gRy3Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","WHWK"],"gpt_icon":0},{"id":"2557356845","title":"WhiteHawk Therapeutics Inc - Anticipates Cash Runway Into 2028","url":"https://stock-news.laohu8.com/highlight/detail?id=2557356845","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2557356845?lang=en_us&edition=fundamental","pubTime":"2025-08-07 20:00","pubTimestamp":1754568008,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250807:nTUA5CCQRH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["WHWK","BK4139"],"gpt_icon":0},{"id":"2556814277","title":"Whitehawk Therapeutics Inc  expected to post earnings of 49 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2556814277","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2556814277?lang=en_us&edition=fundamental","pubTime":"2025-08-01 22:36","pubTimestamp":1754058965,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc  expected to post earnings of49cents a share - Earnings Preview Whitehawk Therapeutics Inc WHWK.OQ WHWK.O is expected to  show a rise in quarterly revenue when it reports  r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250801:nL8N3TT26S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK"],"gpt_icon":0},{"id":"2553464253","title":"Whitehawk Therapeutics Inc. to Participate in BTIG Virtual Biotechnology Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2553464253","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2553464253?lang=en_us&edition=fundamental","pubTime":"2025-07-22 20:01","pubTimestamp":1753185688,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc., an oncology therapeutics company, is set to participate in the BTIG Virtual Biotechnology Conference on July 29-30, 2025. The company, known for applying advanced technologies to established tumor biology to improve ADC cancer treatments, will be represented by its management at the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on July 22, 2025, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250722:nNDLpSCw7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK","BK4139"],"gpt_icon":0},{"id":"2544848161","title":"Whitehawk Therapeutics Inc. to Participate in H.C. Wainwright \"HCW@Home\" Series","url":"https://stock-news.laohu8.com/highlight/detail?id=2544848161","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2544848161?lang=en_us&edition=fundamental","pubTime":"2025-06-19 20:00","pubTimestamp":1750334430,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc., a company specializing in oncology therapeutics, will participate in the virtual H.C. Wainwright \"HCW@Home\" series on June 26, 2025. Dave Lennon, PhD, President and CEO, and David Dornan, PhD, Chief Scientific Officer, will represent the company at the event.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via PR Newswire  on June 19, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250619:nNDL2JbD7T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","WHWK"],"gpt_icon":0},{"id":"2543630173","title":"Whitehawk Therapeutics Inc. Conducted Annual Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2543630173","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543630173?lang=en_us&edition=fundamental","pubTime":"2025-06-14 04:39","pubTimestamp":1749847185,"startTime":"0","endTime":"0","summary":"Whitehawk Therapeutics Inc. held its annual meeting of stockholders on June 11, 2025. During the meeting, the election of three Class II directors was approved. Additionally, the compensation of executive officers was approved on an advisory basis. The appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was also ratified.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Whitehawk Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on June 13, 2025, and is solely responsible for the information contained t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250613:nNDL9nNrNK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WHWK","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.whitehawktx.com","stockEarnings":[{"period":"1week","weight":-0.0683},{"period":"1month","weight":0.0404},{"period":"3month","weight":0.1658},{"period":"6month","weight":0.1837},{"period":"1year","weight":-0.0373},{"period":"ytd","weight":-0.2647}],"compareEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":-0.0024},{"period":"3month","weight":0.037},{"period":"6month","weight":0.142},{"period":"1year","weight":0.1281},{"period":"ytd","weight":0.1633}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Aadi Bioscience, Inc., a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa. The company is also involved in evaluating FYARRO in cancers, including indications targeting specific genomic alterations that activate the mTOR pathway. Aadi Bioscience, Inc. was incorporated in 2007 and is headquartered in Pacific Palisades, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.428571,"avgChangeRate":0.179486},{"month":2,"riseRate":0.285714,"avgChangeRate":-0.0383},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.227585},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.018337},{"month":5,"riseRate":0.857143,"avgChangeRate":0.190811},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.069397},{"month":7,"riseRate":0.375,"avgChangeRate":-0.025419},{"month":8,"riseRate":0.625,"avgChangeRate":0.031865},{"month":9,"riseRate":0.625,"avgChangeRate":0.003135},{"month":10,"riseRate":0.125,"avgChangeRate":-0.092738},{"month":11,"riseRate":0.625,"avgChangeRate":0.077853},{"month":12,"riseRate":0.375,"avgChangeRate":-0.089806}],"exchange":"NASDAQ","name":"Whitehawk Therapeutics, Inc.","nameEN":"Whitehawk Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Whitehawk Therapeutics, Inc.(WHWK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Whitehawk Therapeutics, Inc.(WHWK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Whitehawk Therapeutics, Inc.,WHWK,Whitehawk Therapeutics, Inc.股票,Whitehawk Therapeutics, Inc.股票老虎,Whitehawk Therapeutics, Inc.股票老虎国际,Whitehawk Therapeutics, Inc.行情,Whitehawk Therapeutics, Inc.股票行情,Whitehawk Therapeutics, Inc.股价,Whitehawk Therapeutics, Inc.股市,Whitehawk Therapeutics, Inc.股票价格,Whitehawk Therapeutics, Inc.股票交易,Whitehawk Therapeutics, Inc.股票购买,Whitehawk Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Whitehawk Therapeutics, Inc.(WHWK),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Whitehawk Therapeutics, Inc.(WHWK) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction